You just read:

VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease

News provided by

VM BioPharma

Aug 02, 2016, 09:00 ET